GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004593628 | Skin | cSCC | negative regulation of phosphate metabolic process | 160/4864 | 441/18723 | 8.89e-07 | 1.63e-05 | 160 |
GO:001056328 | Skin | cSCC | negative regulation of phosphorus metabolic process | 160/4864 | 442/18723 | 1.04e-06 | 1.85e-05 | 160 |
GO:004232626 | Skin | cSCC | negative regulation of phosphorylation | 137/4864 | 385/18723 | 1.63e-05 | 1.99e-04 | 137 |
GO:000189223 | Skin | cSCC | embryonic placenta development | 39/4864 | 82/18723 | 2.08e-05 | 2.43e-04 | 39 |
GO:006145825 | Skin | cSCC | reproductive system development | 149/4864 | 427/18723 | 2.30e-05 | 2.65e-04 | 149 |
GO:004860824 | Skin | cSCC | reproductive structure development | 148/4864 | 424/18723 | 2.40e-05 | 2.74e-04 | 148 |
GO:000193326 | Skin | cSCC | negative regulation of protein phosphorylation | 123/4864 | 342/18723 | 2.48e-05 | 2.82e-04 | 123 |
GO:005134829 | Skin | cSCC | negative regulation of transferase activity | 100/4864 | 268/18723 | 2.60e-05 | 2.94e-04 | 100 |
GO:000189024 | Skin | cSCC | placenta development | 60/4864 | 144/18723 | 2.84e-05 | 3.17e-04 | 60 |
GO:006071122 | Skin | cSCC | labyrinthine layer development | 23/4864 | 44/18723 | 1.74e-04 | 1.49e-03 | 23 |
GO:00610998 | Skin | cSCC | negative regulation of protein tyrosine kinase activity | 17/4864 | 31/18723 | 5.90e-04 | 4.27e-03 | 17 |
GO:0006469110 | Skin | cSCC | negative regulation of protein kinase activity | 74/4864 | 212/18723 | 2.36e-03 | 1.37e-02 | 74 |
GO:006109721 | Skin | cSCC | regulation of protein tyrosine kinase activity | 36/4864 | 90/18723 | 2.48e-03 | 1.42e-02 | 36 |
GO:0033673110 | Skin | cSCC | negative regulation of kinase activity | 81/4864 | 237/18723 | 2.95e-03 | 1.64e-02 | 81 |
GO:00507323 | Skin | cSCC | negative regulation of peptidyl-tyrosine phosphorylation | 25/4864 | 59/18723 | 4.46e-03 | 2.29e-02 | 25 |
GO:001820923 | Skin | cSCC | peptidyl-serine modification | 108/4864 | 338/18723 | 7.73e-03 | 3.60e-02 | 108 |
GO:0010563113 | Thyroid | PTC | negative regulation of phosphorus metabolic process | 219/5968 | 442/18723 | 4.47e-15 | 3.07e-13 | 219 |
GO:0045936113 | Thyroid | PTC | negative regulation of phosphate metabolic process | 218/5968 | 441/18723 | 7.08e-15 | 4.75e-13 | 218 |
GO:0001933113 | Thyroid | PTC | negative regulation of protein phosphorylation | 173/5968 | 342/18723 | 3.46e-13 | 1.75e-11 | 173 |
GO:0042326113 | Thyroid | PTC | negative regulation of phosphorylation | 189/5968 | 385/18723 | 1.00e-12 | 4.64e-11 | 189 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GGN | SNV | Missense_Mutation | novel | c.1270N>T | p.Gly424Cys | p.G424C | Q86UU5 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.835) | TCGA-AC-A62X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GGN | SNV | Missense_Mutation | novel | c.13C>A | p.Gln5Lys | p.Q5K | Q86UU5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.953) | TCGA-E2-A2P6-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
GGN | SNV | Missense_Mutation | novel | c.1646N>A | p.Arg549His | p.R549H | Q86UU5 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.88) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
GGN | SNV | Missense_Mutation | | c.1893N>G | p.Ile631Met | p.I631M | Q86UU5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.975) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GGN | SNV | Missense_Mutation | novel | c.1667N>A | p.Val556Glu | p.V556E | Q86UU5 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.702) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
GGN | insertion | In_Frame_Ins | novel | c.1104_1105insAGC | p.Gly368_Ala369insSer | p.G368_A369insS | Q86UU5 | protein_coding | | | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD |
GGN | SNV | Missense_Mutation | | c.698N>T | p.Ala233Val | p.A233V | Q86UU5 | protein_coding | tolerated_low_confidence(0.38) | benign(0.005) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GGN | SNV | Missense_Mutation | | c.1648G>A | p.Glu550Lys | p.E550K | Q86UU5 | protein_coding | tolerated_low_confidence(0.11) | benign(0.091) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GGN | SNV | Missense_Mutation | | c.52N>A | p.Gln18Lys | p.Q18K | Q86UU5 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.533) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GGN | SNV | Missense_Mutation | | c.1813N>T | p.Arg605Cys | p.R605C | Q86UU5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.992) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |